Literature DB >> 1689662

Functional properties of CD19+ B lymphocytes positively selected from buffy coats by immunomagnetic separation.

S Funderud1, B Erikstein, H C Asheim, K Nustad, T Stokke, H K Blomhoff, H Holte, E B Smeland.   

Abstract

Here we report that human B lymphocytes can be positively selected directly from buffy coats applying the anti-CD19 antibody AB1 coupled to magnetic beads. This isolation protocol is highly efficient and the isolated cell population is of very high purity and viability. As judged by cell cycle analysis and various parameters for cell activation, the cells are still in a resting state after isolation. Furthermore, different functional assays have shown that the isolation procedure does not interfere with either activation or proliferation/differentiation of CD19 selected cells as compared to negatively isolated cells. As a consequence of cross-linking during the isolation process, the CD19 antigen is temporarily down-regulated as measured by AB1 binding. Despite this decreased expression, monoclonal antibodies to the CD19 antigen nevertheless inhibited anti-mu plus B cell growth factor induced B cell activation as reported also for negatively isolated cells. Taken together, the presented data strongly suggest that B cells isolated through the CD19 antigen can be used in critical functional assays.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1689662     DOI: 10.1002/eji.1830200129

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  14 in total

1.  Cell cycle-specific expression and nuclear binding of DNA polymerase alpha.

Authors:  T Stokke; B Erikstein; H Holte; S Funderud; H B Steen
Journal:  Mol Cell Biol       Date:  1991-06       Impact factor: 4.272

2.  Invasin of Yersinia pseudotuberculosis activates human peripheral B cells.

Authors:  E Lundgren; N Carballeira; R Vazquez; E Dubinina; H Bränden; H Persson; H Wolf-Watz
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

3.  Defective neutrophil and lymphocyte function in leucocyte adhesion deficiency.

Authors:  Y L Lau; L C Low; B M Jones; J W Lawton
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

4.  Alloantigen presentation by B cells: analysis of the requirement for B-cell activation.

Authors:  J L Wilson; A C Cunningham; J A Kirby
Journal:  Immunology       Date:  1995-11       Impact factor: 7.397

5.  Expansion of mycobacterium-reactive gamma delta T cells by a subset of memory helper T cells.

Authors:  L M Vila; H M Haftel; H S Park; M S Lin; N C Romzek; S M Hanash; J Holoshitz
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

6.  Secretion of parasite-specific immunoglobulin G by purified blood B lymphocytes from immune individuals after in vitro stimulation with recombinant Plasmodium falciparum merozoite surface protein-119 antigen.

Authors:  O Garraud; A Diouf; I Holm; C M Nguer; A Spiegel; R Perraut; S Longacre
Journal:  Immunology       Date:  1999-06       Impact factor: 7.397

7.  Autostimulatory effects of IL-6 on excessive B cell differentiation in patients with systemic lupus erythematosus: analysis of IL-6 production and IL-6R expression.

Authors:  A Kitani; M Hara; T Hirose; M Harigai; K Suzuki; M Kawakami; Y Kawaguchi; T Hidaka; M Kawagoe; H Nakamura
Journal:  Clin Exp Immunol       Date:  1992-04       Impact factor: 4.330

8.  Defective B-cell and regulatory T-cell function in Wiskott-Aldrich syndrome.

Authors:  Y L Lau; B M Jones; L C Low; S N Wong; N K Leung
Journal:  Eur J Pediatr       Date:  1992-09       Impact factor: 3.183

9.  Differential effects of interleukin-2 and interleukin-4 on immunomodulatory role of platelet-activating factor in human B cells.

Authors:  C L Patke; C G Green; W T Shearer
Journal:  Clin Diagn Lab Immunol       Date:  1994-07

10.  Lymphotoxin-alpha is an important autocrine factor for CD40 + interleukin-4-mediated B-cell activation in normal and atopic donors.

Authors:  M Worm; K Ebermayer; B Henz
Journal:  Immunology       Date:  1998-07       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.